CN1490321A - 槐角黄酮有效部位、生产方法及其应用 - Google Patents
槐角黄酮有效部位、生产方法及其应用 Download PDFInfo
- Publication number
- CN1490321A CN1490321A CNA031562825A CN03156282A CN1490321A CN 1490321 A CN1490321 A CN 1490321A CN A031562825 A CNA031562825 A CN A031562825A CN 03156282 A CN03156282 A CN 03156282A CN 1490321 A CN1490321 A CN 1490321A
- Authority
- CN
- China
- Prior art keywords
- extract
- flavonol
- fructus sophorae
- isoflavones
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 229930003944 flavone Natural products 0.000 title claims abstract description 61
- 235000011949 flavones Nutrition 0.000 title claims abstract description 61
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 title claims abstract description 38
- 150000002212 flavone derivatives Chemical class 0.000 title claims abstract description 38
- 238000004519 manufacturing process Methods 0.000 title description 9
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 71
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 71
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 claims abstract description 53
- 235000011957 flavonols Nutrition 0.000 claims abstract description 53
- 150000007946 flavonol Chemical class 0.000 claims abstract description 52
- 238000000034 method Methods 0.000 claims abstract description 45
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 39
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 13
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 11
- 230000008569 process Effects 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims abstract description 5
- 206010020772 Hypertension Diseases 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims description 213
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 159
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- 229930003935 flavonoid Natural products 0.000 claims description 38
- 235000017173 flavonoids Nutrition 0.000 claims description 38
- 239000000047 product Substances 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- 238000002360 preparation method Methods 0.000 claims description 35
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 27
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 25
- 239000002904 solvent Substances 0.000 claims description 24
- 150000002213 flavones Chemical class 0.000 claims description 23
- 238000010828 elution Methods 0.000 claims description 21
- 239000011347 resin Substances 0.000 claims description 21
- 229920005989 resin Polymers 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000000605 extraction Methods 0.000 claims description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000008103 glucose Substances 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- -1 flavonoid compound Chemical class 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
- 238000006460 hydrolysis reaction Methods 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- 208000003351 Melanosis Diseases 0.000 claims description 6
- 206010039966 Senile dementia Diseases 0.000 claims description 6
- 208000029078 coronary artery disease Diseases 0.000 claims description 6
- 230000009245 menopause Effects 0.000 claims description 6
- 230000009759 skin aging Effects 0.000 claims description 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 5
- 206010008132 Cerebral thrombosis Diseases 0.000 claims description 5
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims description 5
- 239000004952 Polyamide Substances 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 229920002647 polyamide Polymers 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- VSRVRBXGIRFARR-CIYSLCTESA-N Neohesperidose Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 VSRVRBXGIRFARR-CIYSLCTESA-N 0.000 claims description 4
- 206010030247 Oestrogen deficiency Diseases 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 4
- VSRVRBXGIRFARR-OUEGHFHCSA-N alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranose Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O VSRVRBXGIRFARR-OUEGHFHCSA-N 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 229910021645 metal ion Inorganic materials 0.000 claims description 4
- 150000004043 trisaccharides Chemical class 0.000 claims description 4
- 239000003021 water soluble solvent Substances 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 230000032683 aging Effects 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 229930182486 flavonoid glycoside Natural products 0.000 claims description 3
- 150000007955 flavonoid glycosides Chemical class 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 2
- 229920005654 Sephadex Polymers 0.000 claims description 2
- 239000012507 Sephadex™ Substances 0.000 claims description 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004411 aluminium Substances 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052788 barium Inorganic materials 0.000 claims description 2
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 239000011833 salt mixture Substances 0.000 claims description 2
- 238000000638 solvent extraction Methods 0.000 claims description 2
- 229910052712 strontium Inorganic materials 0.000 claims description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052726 zirconium Inorganic materials 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000037093 Menstruation Disturbances Diseases 0.000 claims 1
- 206010027339 Menstruation irregular Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011669 selenium Substances 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 13
- 235000013399 edible fruits Nutrition 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 7
- 206010012289 Dementia Diseases 0.000 abstract 1
- 235000013376 functional food Nutrition 0.000 abstract 1
- 150000002215 flavonoids Chemical class 0.000 description 33
- 230000000694 effects Effects 0.000 description 32
- 241000700159 Rattus Species 0.000 description 28
- 238000012360 testing method Methods 0.000 description 21
- 244000046101 Sophora japonica Species 0.000 description 18
- 235000010586 Sophora japonica Nutrition 0.000 description 18
- CHZJRGNDJLJLAW-RIQJQHKOSA-N (8r,9s,13s,14s,16r,17r)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-16,17-diol Chemical group C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1C[C@@H](O)[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 CHZJRGNDJLJLAW-RIQJQHKOSA-N 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000013641 positive control Substances 0.000 description 13
- 241000219784 Sophora Species 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- 230000002265 prevention Effects 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 238000004809 thin layer chromatography Methods 0.000 description 12
- 238000004064 recycling Methods 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 9
- 230000001076 estrogenic effect Effects 0.000 description 9
- 210000004291 uterus Anatomy 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 230000006837 decompression Effects 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 7
- 235000013336 milk Nutrition 0.000 description 7
- 239000008267 milk Substances 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000003075 phytoestrogen Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- VOXZDWNPVJITMN-WKUFJEKOSA-N estradiol group Chemical group [C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 VOXZDWNPVJITMN-WKUFJEKOSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 102000004067 Osteocalcin Human genes 0.000 description 4
- 108090000573 Osteocalcin Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037182 bone density Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 102000011759 adducin Human genes 0.000 description 3
- 108010076723 adducin Proteins 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000002905 metal composite material Substances 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 208000035824 paresthesia Diseases 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 241000692853 Sophora chrysophylla Species 0.000 description 2
- 241000692855 Sophora tetraptera Species 0.000 description 2
- ISQRJFLLIDGZEP-CMWLGVBASA-N Sophoricoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)C=C1 ISQRJFLLIDGZEP-CMWLGVBASA-N 0.000 description 2
- ISQRJFLLIDGZEP-KJRRRBQDSA-N Sophoricoside Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1ccc(C=2C(=O)c3c(O)cc(O)cc3OC=2)cc1 ISQRJFLLIDGZEP-KJRRRBQDSA-N 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 208000024732 dysthymic disease Diseases 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 231100000243 mutagenic effect Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229950007863 nilestriol Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 235000021262 sour milk Nutrition 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 208000012991 uterine carcinoma Diseases 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 244000182264 Lucuma nervosa Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 description 1
- 241000596420 Podalyria sericea Species 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 240000003968 Sophora davidii Species 0.000 description 1
- 235000007245 Sophora davidii Nutrition 0.000 description 1
- 241001109619 Sophora fernandeziana Species 0.000 description 1
- 241001594111 Sophora fraseri Species 0.000 description 1
- 241001290706 Sophora macrocarpa Species 0.000 description 1
- 241001109618 Sophora masafuerana Species 0.000 description 1
- 241001398492 Sophora moorcroftiana Species 0.000 description 1
- 241001358144 Sophora pachycarpa Species 0.000 description 1
- 241000212967 Sophora secundiflora Species 0.000 description 1
- 244000087639 Sophora tomentosa Species 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 238000002479 acid--base titration Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000008271 cosmetic emulsion Substances 0.000 description 1
- 235000012777 crisp bread Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000005474 octanoate group Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 229940094984 other estrogen in atc Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229920006122 polyamide resin Polymers 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (18)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031562825A CN100366628C (zh) | 2003-09-03 | 2003-09-03 | 槐角黄酮有效部位、生产方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031562825A CN100366628C (zh) | 2003-09-03 | 2003-09-03 | 槐角黄酮有效部位、生产方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1490321A true CN1490321A (zh) | 2004-04-21 |
CN100366628C CN100366628C (zh) | 2008-02-06 |
Family
ID=34156908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031562825A Expired - Fee Related CN100366628C (zh) | 2003-09-03 | 2003-09-03 | 槐角黄酮有效部位、生产方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100366628C (zh) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005343872A (ja) * | 2004-06-07 | 2005-12-15 | Kao Corp | アロマターゼ活性化剤 |
WO2008051586A3 (en) * | 2006-10-24 | 2008-09-25 | David W Krempin | Anti-resorptive and bone building dietary supplements and methods of use |
US7887851B2 (en) | 2004-06-07 | 2011-02-15 | Kao Corporation | Aromatase activator |
US7897184B1 (en) | 2009-08-13 | 2011-03-01 | Access Business Group International Llc | Topical composition with skin lightening effect |
CN102127046A (zh) * | 2010-12-06 | 2011-07-20 | 南京大学 | 4′,5-二羟基-7-[4-(n,n-二乙氨基)丁氧基]异黄酮及其制备方法和应用 |
CN101709057B (zh) * | 2009-10-23 | 2011-08-17 | 四川杨天药业有限公司 | 染料木素的提取方法 |
CN101357913B (zh) * | 2008-08-29 | 2011-09-07 | 贵州大学 | 从槐角中提取黄酮类成分并提取山奈素的方法 |
CN103191237A (zh) * | 2010-12-28 | 2013-07-10 | 江西青峰药业有限公司 | 乙醇回流提取的枳实或枳壳总黄酮提取物及其用途 |
CN103191236A (zh) * | 2010-12-28 | 2013-07-10 | 江西青峰药业有限公司 | 乙醇回流提取的枳实或枳壳总黄酮提取物及其用途 |
US9193607B1 (en) | 2015-02-17 | 2015-11-24 | Maxia Investments, LLC | Water treatment for high-efficiency cleaning |
CN105343158A (zh) * | 2015-12-03 | 2016-02-24 | 中国人民解放军白求恩医务士官学校 | 一种具有广谱抗肿瘤活性的槐角总黄酮提取物及其制备方法与应用 |
CN105646621A (zh) * | 2016-02-16 | 2016-06-08 | 天津科技大学 | 漾濞核桃青皮中一种异黄酮苷及其制备方法和抗炎用途 |
CN106474181A (zh) * | 2016-10-20 | 2017-03-08 | 黑龙江省中医药科学院 | 一种治疗女性泌尿生殖道萎缩的栓剂及其制备方法 |
CN107397751A (zh) * | 2017-06-07 | 2017-11-28 | 新乡医学院 | 治疗阿尔海默式综合症的药物组合物及其应用 |
CN108383885A (zh) * | 2018-05-02 | 2018-08-10 | 孙波 | 从槐角中提取槐角苷的工艺及其在抗炎症中的用途 |
CN111349128A (zh) * | 2018-12-20 | 2020-06-30 | 上海医药工业研究院 | 黄酮醇衍生物及其制备方法和应用 |
CN111643511A (zh) * | 2020-07-27 | 2020-09-11 | 吉林省现代中药工程研究中心有限公司 | 槐角苷在制备防治前列腺疾病的药物中的应用 |
CN114949033A (zh) * | 2022-03-08 | 2022-08-30 | 天津德铭继康医疗科技有限公司 | 一种槐角提取物制备方法及其在治疗和/或预防银屑病药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1199648C (zh) * | 2001-06-06 | 2005-05-04 | 杜宁 | 槐甙的应用 |
CN1414005A (zh) * | 2001-10-22 | 2003-04-30 | 张敏红 | 黄酮醇甙提取工艺 |
CN1183150C (zh) * | 2002-11-21 | 2005-01-05 | 吉林天药科技股份有限公司 | 槐属苷的制备方法、药物制剂及医药新用途 |
CN1224395C (zh) * | 2003-01-27 | 2005-10-26 | 吉林天药科技股份有限公司 | 槐属苷的医药新用途 |
-
2003
- 2003-09-03 CN CNB031562825A patent/CN100366628C/zh not_active Expired - Fee Related
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7887851B2 (en) | 2004-06-07 | 2011-02-15 | Kao Corporation | Aromatase activator |
US9222079B2 (en) | 2004-06-07 | 2015-12-29 | Kao Corporation | Aromatase activator |
JP2005343872A (ja) * | 2004-06-07 | 2005-12-15 | Kao Corp | アロマターゼ活性化剤 |
EP2415469A1 (en) * | 2006-10-24 | 2012-02-08 | David W. Krempin | Anti-Resorptive and Bone Building Dietary Supplements and Methods of Use |
WO2008051586A3 (en) * | 2006-10-24 | 2008-09-25 | David W Krempin | Anti-resorptive and bone building dietary supplements and methods of use |
WO2008051594A3 (en) * | 2006-10-24 | 2008-10-09 | David W Krempin | Anti-resorptive and bone building dietary supplements and methods of use |
US11207368B2 (en) | 2006-10-24 | 2021-12-28 | Murray Mary A | Anti-resorptive and bone building dietary supplements and methods of use |
US9446087B2 (en) | 2006-10-24 | 2016-09-20 | David W. Krempin | Anti-resorptive and bone building dietary supplements and methods of use |
CN101357913B (zh) * | 2008-08-29 | 2011-09-07 | 贵州大学 | 从槐角中提取黄酮类成分并提取山奈素的方法 |
US7897184B1 (en) | 2009-08-13 | 2011-03-01 | Access Business Group International Llc | Topical composition with skin lightening effect |
US8202556B2 (en) | 2009-08-13 | 2012-06-19 | Access Business Group International Llc | Topical composition with skin lightening effect |
CN101709057B (zh) * | 2009-10-23 | 2011-08-17 | 四川杨天药业有限公司 | 染料木素的提取方法 |
CN102127046B (zh) * | 2010-12-06 | 2012-08-22 | 南京大学 | 4′,5-二羟基-7-[4-(n,n-二乙氨基)丁氧基]异黄酮及其制备方法和应用 |
CN102127046A (zh) * | 2010-12-06 | 2011-07-20 | 南京大学 | 4′,5-二羟基-7-[4-(n,n-二乙氨基)丁氧基]异黄酮及其制备方法和应用 |
CN103191237A (zh) * | 2010-12-28 | 2013-07-10 | 江西青峰药业有限公司 | 乙醇回流提取的枳实或枳壳总黄酮提取物及其用途 |
CN103191236A (zh) * | 2010-12-28 | 2013-07-10 | 江西青峰药业有限公司 | 乙醇回流提取的枳实或枳壳总黄酮提取物及其用途 |
US9193607B1 (en) | 2015-02-17 | 2015-11-24 | Maxia Investments, LLC | Water treatment for high-efficiency cleaning |
CN105343158A (zh) * | 2015-12-03 | 2016-02-24 | 中国人民解放军白求恩医务士官学校 | 一种具有广谱抗肿瘤活性的槐角总黄酮提取物及其制备方法与应用 |
CN105646621A (zh) * | 2016-02-16 | 2016-06-08 | 天津科技大学 | 漾濞核桃青皮中一种异黄酮苷及其制备方法和抗炎用途 |
CN105646621B (zh) * | 2016-02-16 | 2018-01-19 | 天津科技大学 | 漾濞核桃青皮中一种异黄酮苷及其制备方法和抗炎用途 |
CN106474181A (zh) * | 2016-10-20 | 2017-03-08 | 黑龙江省中医药科学院 | 一种治疗女性泌尿生殖道萎缩的栓剂及其制备方法 |
CN107397751A (zh) * | 2017-06-07 | 2017-11-28 | 新乡医学院 | 治疗阿尔海默式综合症的药物组合物及其应用 |
CN108383885B (zh) * | 2018-05-02 | 2021-07-23 | 孙波 | 从槐角中提取槐角苷的工艺及其在抗炎症中的用途 |
CN108383885A (zh) * | 2018-05-02 | 2018-08-10 | 孙波 | 从槐角中提取槐角苷的工艺及其在抗炎症中的用途 |
CN111349128A (zh) * | 2018-12-20 | 2020-06-30 | 上海医药工业研究院 | 黄酮醇衍生物及其制备方法和应用 |
CN111349128B (zh) * | 2018-12-20 | 2023-01-06 | 上海医药工业研究院 | 黄酮醇衍生物及其制备方法和应用 |
CN111643511A (zh) * | 2020-07-27 | 2020-09-11 | 吉林省现代中药工程研究中心有限公司 | 槐角苷在制备防治前列腺疾病的药物中的应用 |
CN114949033A (zh) * | 2022-03-08 | 2022-08-30 | 天津德铭继康医疗科技有限公司 | 一种槐角提取物制备方法及其在治疗和/或预防银屑病药物中的应用 |
CN114949033B (zh) * | 2022-03-08 | 2023-09-08 | 天津德铭继康医疗科技有限公司 | 一种槐角提取物制备方法及其在治疗和/或预防银屑病药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN100366628C (zh) | 2008-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1490321A (zh) | 槐角黄酮有效部位、生产方法及其应用 | |
CN1265725C (zh) | 具有延缓衰老和增加骨密度功能的保健食品 | |
CN1267727C (zh) | 检测银杏叶组合物中银杏酸的方法 | |
CN1757743A (zh) | 含异黄酮的组合物 | |
CN1799574A (zh) | 治疗抑郁症的药物 | |
CN1212966A (zh) | 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙 | |
CN1687099A (zh) | 射干总黄酮提取物及其制备方法和其在药物制备中的应用 | |
CN1824763A (zh) | 五脏滋补酒及其制备工艺 | |
CN1849128A (zh) | 选择性抑制人体内雌激素产生以及提供雌激素的作用 | |
CN1589246A (zh) | 萃取方法和提纯有效物质的方法 | |
CN1731978A (zh) | 具有抗氧化活性和抗衰老活性的中国紫荆的提取物,以及含有该提取物并用于抗氧化、皮肤衰老防护和改善皱纹的化妆品组合物 | |
CN1791393A (zh) | 用于抑制或预防骨密度减少的组合物、食品和饮料 | |
CN1853513A (zh) | 一种具有缓解体力疲劳作用的运动饮料 | |
CN1649607A (zh) | 一种从黑稻中提取花色素苷的方法及其组合物 | |
CN101028261A (zh) | 紫花牡荆素用于制备抗经前期综合症产品的用途 | |
CN1253172C (zh) | 抗变态反应剂、含有它的药品、食品或化妆品及它们的制备方法 | |
JPWO2008016105A1 (ja) | 骨疾患の予防及び/又は治療用医薬組成物、その組成物を含有する機能性食品もしくは健康食品、並びにその組成物を有効成分とする医薬製剤 | |
CN100427112C (zh) | 一种具降血压作用的桑椹活性提取物及其制备方法、用途 | |
CN1901926A (zh) | 含有葫芦科植物提取物或者从其中分离的具有抗脂肪形成和抗肥胖症活性的纯化提取物的组合物 | |
CN1522754A (zh) | 抗病毒增免疫治疗性功能障碍物的萃取及制剂 | |
CN1890232A (zh) | 类黄酮衍生物 | |
KR102612796B1 (ko) | 신규한 락토바실러스 파라카제이 js1 균주 및 이의 용도 | |
CN1684660A (zh) | 含有白头翁提取物作为主要成分并具有增白效果的化妆品组合物 | |
CN1730083A (zh) | 元合片及其制备方法 | |
KR101127437B1 (ko) | 비만 또는 당뇨병 예방 및 치료용 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING SHENKELIANHUA SCIENCE CO., LTD. Free format text: FORMER OWNER: BEIJING ZHONGSHEN PATENT SCIENCE CO., LTD.; WEI XIANHUA Effective date: 20080404 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080404 Address after: No. 1, building 6, building 6028, international science and Technology Pioneer Park, No. 100085 information road, Beijing, Haidian District: A Patentee after: Beijing Shenkelianhua Technology Co., Ltd. Address before: No. 6, No. two, 4-201 Longteng court, East Dragon Road, Beijing, Changping District: 102208 Co-patentee before: Wei Xianhua Patentee before: Beijing Zhong Shen Patent Technology Co., Ltd. |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080206 |